Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Debt Ratio (2014 - 2023)

Updated

Grace Therapeutics' (GRCE) Debt Ratio was 0.00 for fiscal Q3 2024 (quarter ended Dec 31, 2023).

Analysis

Grace Therapeutics (GRCE) Debt Ratio (2014 - 2023) Analysis & Trends

Dating back to fiscal Q2 2015, Grace Therapeutics' Debt Ratio record includes 5 quarters.

  • By fiscal year, Debt Ratio came in at 0.04 in FY2019.
  • The fiscal Q3 2024 figure ranks as the lowest quarterly Debt Ratio since fiscal Q1 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 0.33
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 0.23
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 0.55
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 0.41
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -0.05
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 0.56
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 0.51
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 0.31
10 Grace Therapeutics 35.10 Mn -35.61 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 0.00
Mar 31, 2023 0.00
Mar 31, 2019 0.04
Jun 30, 2018 0.00
Aug 31, 2014 0.00
API Access

Grace Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=GRCE&period=max&api_key=YOUR_API_KEY